EXPD vs LAB · P/E 26, rev $10.60B vs rev $174.4M
Expeditors International of Washington, Inc. (EXPD) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
Expeditors International of Washington, Inc. (EXPD) is a integrated freight & logistics company listed on NYSE.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported EXPD revenue for 2024-12-31 was $10.60B. Net income was $811.6M. Revenue was up 14.0% from 2023-12-31 to 2024-12-31. EXPD currently screens at market cap $21.01B and trailing P/E 26.0.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
EXPD currently screens at market cap $21.01B and trailing P/E 26.0. LAB currently screens at market cap $317.1M.
Not investment advice. Open the EXPD and LAB stock pages for the full models.
Not investment advice.